WallStSmart

AngioDynamics Inc (ANGO)vsResMed Inc (RMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ResMed Inc generates 1666% more annual revenue ($5.65B vs $320.17M). RMD leads profitability with a 27.0% profit margin vs -11.5%. RMD appears more attractively valued with a PEG of 1.33. RMD earns a higher WallStSmart Score of 65/100 (C+).

ANGO

Hold

40

out of 100

Grade: D

Growth: 4.0Profit: 2.0Value: 7.0Quality: 4.8
Piotroski: 3/9Altman Z: -0.06

RMD

Buy

65

out of 100

Grade: C+

Growth: 6.0Profit: 9.0Value: 4.7Quality: 9.0
Piotroski: 5/9Altman Z: 4.53
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ANGOUndervalued (+38.4%)

Margin of Safety

+38.4%

Fair Value

$18.45

Current Price

$15.27

$3.18 discount

UndervaluedFair: $18.45Overvalued
RMDSignificantly Overvalued (-24.1%)

Margin of Safety

-24.1%

Fair Value

$209.29

Current Price

$218.27

$8.98 premium

UndervaluedFair: $209.29Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ANGO0 strengths · Avg: 0/10

No standout strengths identified

RMD6 strengths · Avg: 9.2/10
Operating MarginProfitability
30.9%10/10

Strong operational efficiency at 30.9%

Altman Z-ScoreHealth
4.5310/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
23.1%9/10

Every $100 of equity generates 23 in profit

Profit MarginProfitability
27.0%9/10

Keeps 27 of every $100 in revenue as profit

Debt/EquityHealth
0.139/10

Conservative balance sheet, low leverage

Free Cash FlowQuality
$1.65B8/10

Generating 1.6B in free cash flow

Areas to Watch

ANGO4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$631.15M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-21.5%2/10

ROE of -21.5% — below average capital efficiency

RMD1 concerns · Avg: 4.0/10
EPS GrowthGrowth
2.4%4/10

2.4% earnings growth

Comparative Analysis Report

WallStSmart Research

Bull Case : ANGO

PEG of 1.41 suggests the stock is reasonably priced for its growth.

Bull Case : RMD

The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.0% and operating margin at 30.9%. PEG of 1.33 suggests the stock is reasonably priced for its growth.

Bear Case : ANGO

The primary concerns for ANGO are EPS Growth, Market Cap, Piotroski F-Score.

Bear Case : RMD

The primary concerns for RMD are EPS Growth.

Key Dynamics to Monitor

ANGO profiles as a turnaround stock while RMD is a mature play — different risk/reward profiles.

RMD carries more volatility with a beta of 0.77 — expect wider price swings.

RMD is growing revenue faster at 8.6% — sustainability is the question.

RMD generates stronger free cash flow (1.6B), providing more financial flexibility.

Bottom Line

RMD scores higher overall (65/100 vs 40/100), backed by strong 27.0% margins. ANGO offers better value entry with a 38.4% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AngioDynamics Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

AngioDynamics, Inc. designs, manufactures and sells various medical, surgical and diagnostic devices for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company is headquartered in Latham, New York.

ResMed Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

Visit Website →

Want to dig deeper into these stocks?